NextCure, Inc. (NASDAQ:NXTC – Free Report) – Stock analysts at HC Wainwright increased their Q2 2026 earnings estimates for NextCure in a research report issued to clients and investors on Wednesday, July 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.93) for the quarter, up from their previous estimate of ($2.09). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.90) per share. HC Wainwright also issued estimates for NextCure’s Q3 2026 earnings at ($2.00) EPS, Q4 2026 earnings at ($2.07) EPS, FY2026 earnings at ($7.88) EPS, FY2027 earnings at ($3.33) EPS, FY2028 earnings at ($3.18) EPS and FY2029 earnings at ($2.17) EPS.
NextCure (NASDAQ:NXTC – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23.
Check Out Our Latest Analysis on NXTC
NextCure Price Performance
Shares of NXTC stock opened at $6.17 on Friday. The stock has a market capitalization of $22.27 million, a PE ratio of -0.36 and a beta of 1.42. The business’s 50 day simple moving average is $4.51 and its 200 day simple moving average is $9.32. NextCure has a one year low of $1.55 and a one year high of $15.74.
Institutional Investors Weigh In On NextCure
Hedge funds and other institutional investors have recently made changes to their positions in the business. Cable Car Capital LP raised its position in NextCure by 13.1% in the 2nd quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after buying an additional 88,040 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of NextCure by 18.6% in the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after purchasing an additional 3,636 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of NextCure by 18.7% during the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after purchasing an additional 5,300 shares in the last quarter. Exome Asset Management LLC bought a new position in shares of NextCure during the fourth quarter valued at about $2,341,000. Finally, AWM Investment Company Inc. purchased a new position in NextCure during the fourth quarter worth about $1,665,000. 42.65% of the stock is owned by institutional investors.
About NextCure
NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.
The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.
Read More
- Five stocks we like better than NextCure
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
